Search

… access to state-of-the-art clinical trials,” adds Christos Fountzilas, MD , NPF Program Director at Roswell Park. “I … access to state-of-the-art clinical trials,” adds Christos Fountzilas, MD , NPF Program Director at Roswell Park. “I …

… chemotherapy, and it becomes progressive.” Dr. Christos Fountzilas “Roswell Park is at the forefront of research on … and radiation in those patients,” says Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … chemotherapy, and it becomes progressive.”   Dr. Christos Fountzilas “Roswell Park is at the forefront of research on …

… in the United States,” notes study co-author  Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … Recognizing the need for better therapeutic options, Dr. Fountzilas and his colleague,  Andrei V. Bakin, PhD , … for selective targeting of p53-mutant cancers,” Dr. Fountzilas adds. “Of note, while PARP inhibitors are approved …

… Department of Pharmacology and Therapeutics; and Christos Fountzilas, MD , Department of Medicine, each received … Department of Pharmacology and Therapeutics; and Christos Fountzilas, MD , Department of Medicine, each received …